You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcetohexamide
Accession NumberDB00414  (APRD00773)
TypeSmall Molecule
GroupsWithdrawn
DescriptionA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Structure
Thumb
Synonyms
1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea
1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
Acetohexamid
Acetohexamida
Acétohexamide
Acetohexamide
Acetohexamidum
N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimelor Tablet 1843 500mgtablet500 mgoralEli Lilly Canada Inc1963-12-311998-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcetohexamideWatson
DimelinShionogi Seiyaku
DymelorLilly
GamadiabetSalvat
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQGC8W08I6I
CAS number968-81-0
WeightAverage: 324.395
Monoisotopic: 324.114377828
Chemical FormulaC15H20N2O4S
InChI KeyVGZSUPCWNCWDAN-UHFFFAOYSA-N
InChI
InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
IUPAC Name
3-(4-acetylbenzenesulfonyl)-1-cyclohexylurea
SMILES
CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Sulfonylurea
  • Cyclohexylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Ketone
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the management of diabetes mellitus type 2 (adult-onset).
PharmacodynamicsAcetohexamide is an intermediate-acting, first-generation oral sulfonylurea. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide has one-third the potency of chlorpropamide, and twice the potency of tolbutamide; however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas.
Mechanism of actionSulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.
Related Articles
AbsorptionRapidly absorbed from the GI tract.
Volume of distributionNot Available
Protein binding90%
Metabolism

Extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects.

SubstrateEnzymesProduct
Acetohexamide
Not Available
HydroxyhexamideDetails
Route of eliminationNot Available
Half lifeElimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.
ClearanceNot Available
ToxicityOral, rat LD50: 5 gm/kg; Oral, mouse LD50: >2500 mg/kg. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9425
Blood Brain Barrier+0.8308
Caco-2 permeable-0.6272
P-glycoprotein substrateNon-substrate0.6406
P-glycoprotein inhibitor INon-inhibitor0.8731
P-glycoprotein inhibitor IINon-inhibitor0.8808
Renal organic cation transporterNon-inhibitor0.8538
CYP450 2C9 substrateSubstrate0.6473
CYP450 2D6 substrateNon-substrate0.8795
CYP450 3A4 substrateNon-substrate0.7171
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5913
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8447
BiodegradationNot ready biodegradable0.8033
Rat acute toxicity2.1793 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8799
hERG inhibition (predictor II)Non-inhibitor0.8982
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Usl pharma inc
  • Watson laboratories inc
  • Eli lilly industries inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point188-190 °CSigal,M.V.,Jr.andVanArendonk,A.M.; US.Patent3,320,312;May16,1967;assigned to Eli Lilly and Company.
water solubility3430 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.44SANGSTER (1993)
logS-2.06ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0483 mg/mLALOGPS
logP1.72ALOGPS
logP1.81ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.31ChemAxon
pKa (Strongest Basic)-7.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.34 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity82.77 m3·mol-1ChemAxon
Polarizability33.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA10BB31
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololAcebutolol may increase the hypoglycemic activities of Acetohexamide.
AcenocoumarolAcetohexamide may increase the anticoagulant activities of Acenocoumarol.
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Acetohexamide.
AlogliptinAlogliptin may increase the hypoglycemic activities of Acetohexamide.
AlprenololAlprenolol may increase the hypoglycemic activities of Acetohexamide.
AripiprazoleThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.
ArotinololArotinolol may increase the hypoglycemic activities of Acetohexamide.
Arsenic trioxideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Atazanavir.
AtenololAtenolol may increase the hypoglycemic activities of Acetohexamide.
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Acetohexamide.
BefunololBefunolol may increase the hypoglycemic activities of Acetohexamide.
BendroflumethiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bendroflumethiazide.
BetamethasoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Betamethasone.
BetaxololBetaxolol may increase the hypoglycemic activities of Acetohexamide.
BevantololBevantolol may increase the hypoglycemic activities of Acetohexamide.
BezafibrateBezafibrate may increase the hypoglycemic activities of Acetohexamide.
BisoprololBisoprolol may increase the hypoglycemic activities of Acetohexamide.
BopindololBopindolol may increase the hypoglycemic activities of Acetohexamide.
BrexpiprazoleThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Brexpiprazole.
BufuralolBufuralol may increase the hypoglycemic activities of Acetohexamide.
BumetanideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide.
BupranololBupranolol may increase the hypoglycemic activities of Acetohexamide.
BuserelinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Buserelin.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Acetohexamide.
CarbocisteineThe risk or severity of adverse effects can be increased when Acetohexamide is combined with Carbocisteine.
CarteololCarteolol may increase the hypoglycemic activities of Acetohexamide.
CarvedilolCarvedilol may increase the hypoglycemic activities of Acetohexamide.
CeliprololCeliprolol may increase the hypoglycemic activities of Acetohexamide.
CeritinibThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ceritinib.
ChloramphenicolThe metabolism of Acetohexamide can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide.
ChlorpropamideAcetohexamide may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorthalidone.
CimetidineThe serum concentration of Acetohexamide can be increased when it is combined with Cimetidine.
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Acetohexamide.
ClofibrateClofibrate may increase the hypoglycemic activities of Acetohexamide.
ClozapineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Danazol.
DarunavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Diazoxide.
DicoumarolAcetohexamide may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dienogest.
DisopyramideAcetohexamide may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.
DulaglutideDulaglutide may increase the hypoglycemic activities of Acetohexamide.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Acetohexamide.
EpinephrineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Epinephrine.
EsmololEsmolol may increase the hypoglycemic activities of Acetohexamide.
EstradiolThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Acetohexamide is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinyl Estradiol.
Ethyl biscoumacetateAcetohexamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethynodiol diacetate.
EtofibrateEtofibrate may increase the hypoglycemic activities of Acetohexamide.
EtonogestrelThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etonogestrel.
EverolimusThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Acetohexamide.
FenofibrateFenofibrate may increase the hypoglycemic activities of Acetohexamide.
FluconazoleThe serum concentration of Acetohexamide can be increased when it is combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Fludrocortisone.
FosamprenavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Fosamprenavir.
FurosemideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Acetohexamide.
GliclazideAcetohexamide may increase the hypoglycemic activities of Gliclazide.
GlimepirideAcetohexamide may increase the hypoglycemic activities of Glimepiride.
GlipizideAcetohexamide may increase the hypoglycemic activities of Glipizide.
GlyburideAcetohexamide may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Histrelin.
HydrochlorothiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Iloperidone.
IndapamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.
IndenololIndenolol may increase the hypoglycemic activities of Acetohexamide.
IndinavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indinavir.
Insulin AspartAcetohexamide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirAcetohexamide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineAcetohexamide may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineAcetohexamide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanAcetohexamide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproAcetohexamide may increase the hypoglycemic activities of Insulin Lispro.
LabetalolLabetalol may increase the hypoglycemic activities of Acetohexamide.
LanreotideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lanreotide.
LanreotideAcetohexamide may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.
LevobunololLevobunolol may increase the hypoglycemic activities of Acetohexamide.
LevonorgestrelThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Levonorgestrel.
LinagliptinLinagliptin may increase the hypoglycemic activities of Acetohexamide.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Acetohexamide.
LiraglutideLiraglutide may increase the hypoglycemic activities of Acetohexamide.
LopinavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.
LurasidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone.
MecaserminAcetohexamide may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Megestrol acetate.
MestranolThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Mestranol.
MethotrimeprazineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.
MethylprednisoloneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone.
MetipranololMetipranolol may increase the hypoglycemic activities of Acetohexamide.
MetolazoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone.
MetoprololMetoprolol may increase the hypoglycemic activities of Acetohexamide.
MetreleptinMetreleptin may increase the hypoglycemic activities of Acetohexamide.
MiconazoleMiconazole may increase the hypoglycemic activities of Acetohexamide.
MifepristoneAcetohexamide may increase the hypoglycemic activities of Mifepristone.
NadololNadolol may increase the hypoglycemic activities of Acetohexamide.
NateglinideAcetohexamide may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Niacin.
NilotinibThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Norgestimate.
OctreotideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.
OctreotideAcetohexamide may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine.
OxprenololOxprenolol may increase the hypoglycemic activities of Acetohexamide.
PaliperidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Paliperidone.
PasireotideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pasireotide.
PasireotideAcetohexamide may increase the hypoglycemic activities of Pasireotide.
PenbutololPenbutolol may increase the hypoglycemic activities of Acetohexamide.
PentamidineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pentamidine.
PentamidineAcetohexamide may increase the hypoglycemic activities of Pentamidine.
PhenindioneAcetohexamide may increase the anticoagulant activities of Phenindione.
PhenprocoumonAcetohexamide may increase the anticoagulant activities of Phenprocoumon.
PindololPindolol may increase the hypoglycemic activities of Acetohexamide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Acetohexamide.
PiperazineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pipotiazine.
PolythiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Polythiazide.
PractololPractolol may increase the hypoglycemic activities of Acetohexamide.
PrednisoloneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisone.
ProbenecidThe protein binding of Acetohexamide can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Progesterone.
PropranololPropranolol may increase the hypoglycemic activities of Acetohexamide.
QuetiapineThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quinethazone.
QuinineAcetohexamide may increase the hypoglycemic activities of Quinine.
RanitidineThe serum concentration of Acetohexamide can be increased when it is combined with Ranitidine.
RepaglinideAcetohexamide may increase the hypoglycemic activities of Repaglinide.
RifampicinThe serum concentration of Acetohexamide can be decreased when it is combined with Rifampicin.
RisperidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ritonavir.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Acetohexamide.
SaquinavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Acetohexamide.
SirolimusThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Acetohexamide.
SotalolSotalol may increase the hypoglycemic activities of Acetohexamide.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Acetohexamide.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Acetohexamide.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Acetohexamide.
SunitinibAcetohexamide may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Temsirolimus.
TimololTimolol may increase the hypoglycemic activities of Acetohexamide.
TipranavirThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tipranavir.
TolazamideAcetohexamide may increase the hypoglycemic activities of Tolazamide.
TolbutamideAcetohexamide may increase the hypoglycemic activities of Tolbutamide.
TorasemideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.
TriamcinoloneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Trichlormethiazide.
TriptorelinThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Acetohexamide.
VildagliptinVildagliptin may increase the hypoglycemic activities of Acetohexamide.
VoriconazoleThe serum concentration of Acetohexamide can be increased when it is combined with Voriconazole.
VorinostatThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Vorinostat.
WarfarinAcetohexamide may increase the anticoagulant activities of Warfarin.
ZiprasidoneThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Molecular Weight:
30374.73 Da
References
  1. Imamura Y, Shimada H: Differential pharmacokinetics of acetohexamide in male Wistar-Imamichi and Sprague-Dawley rats: role of microsomal carbonyl reductase. Biol Pharm Bull. 2005 Jan;28(1):185-7. [PubMed:15635190 ]
  2. Imamura Y, Koga T, Higuchi T, Otagiri M, Sugino E, Hibino S: Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. J Enzyme Inhib. 1997 Feb;11(4):285-92. [PubMed:9208371 ]
  3. Kishimoto M, Kawamori R, Kamada T, Inaba T: Carbonyl reductase activity for acetohexamide in human erythrocytes. Drug Metab Dispos. 1994 May-Jun;22(3):367-70. [PubMed:8070312 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23